Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer

被引：4

作者：

Deshpande, H. A. ^{[1
]}

Sheth, K. ^{[2
]}

Sosa, J. A. ^{[1
]}

Roman, S. ^{[1
]}

机构：

[1] Yale Univ, Sch Med, 333 Cedar St, New Haven, CT 06510 USA

[2] Gujarat Univ, Smt NHL Municipal Med Coll, Ahmadabad, Gujarat, India

来源：

CLINICAL MEDICINE INSIGHTS-ONCOLOGY | 2012年 / 6卷

关键词：

medullary thyroid cancer; pharmacotherapy; tyrosine kinase inhibitors; vandetanib;

D O I：

10.4137/CMO.S8305

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Metastatic and unresectable medullary thyroid carcinoma (MTC) is often difficult to treat as it is relatively unresponsive to radiation and conventional chemotherapy. This emphasizes the importance of the development of targeted therapies for advanced MTC. Vandetanib was approved by the US Food and Drug Administration for the treatment of symptomatic or progressive MTC in patients with advanced disease in April 2011. This therapy proved to be a breakthrough in the management of MTC. We review the efficacy and safety of this novel treatment and other treatments that are being evaluated in this disease.

引用

页码：355 / 362

页数：8

共 28 条

[1] CHEMOTHERAPY OF THYROID-CARCINOMA [J].

AHUJA, S ;

ERNST, H .

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1987, 10 (03) :303-310

[2]

[Anonymous], 2012, MED LETT DRUGS THER, V54, P3

[3] Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature [J].

Benucci, Maurizio ;

Saviola, Gianantonio ;

Manfredi, Mariangela ;

Sarzi-Puttini, Piercarlo ;

Atzeni, Fabiola .

INTERNATIONAL JOURNAL OF RHEUMATOLOGY, 2011, 2011

[4] Guidelines for diagnosis and therapy of MEN type 1 and type 2 [J].

Brandi, ML ;

Gagel, RF ;

Angeli, A ;

Bilezikian, JP ;

Beck-Peccoz, P ;

Bordi, C ;

Conte-Devolx, B ;

Falchetti, A ;

Gheri, RG ;

Libroia, A ;

Lips, CJM ;

Lombardi, G ;

Mannelli, M ;

Pacini, F ;

Pondder, BAJ ;

Raue, F ;

Skogseid, B ;

Tamburrano, G ;

Thakker, RV ;

Thompson, NW ;

Tomassetti, P ;

Tonelli, F ;

Wells, SA ;

Marx, SJ .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (12) :5658-5671

[5] Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474 [J].

Carlomagno, Francesca ;

Guida, Teresa ;

Anaganti, Suresh ;

Provitera, Livia ;

Kjaer, Svend ;

McDonald, Neil Q. ;

Ryan, Anderson J. ;

Santoro, Massimo .

[6] Additive effect of RET polymorphisms on sporadic medullary thyroid carcinoma susceptibility and tumor aggressiveness [J].

Ceolin, Lucieli ;

Siqueira, Debora Rodrigues ;

Ferreira, Carla Vaz ;

Romitti, Mirian ;

Maia, Silvana Cavalcante ;

Leiria, Leonardo ;

Crispim, Daisy ;

Prolla, Patricia Ashton ;

Maia, Ana Luiza .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2012, 166 (05) :847-854

[7] Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer [J].

Deshpande, Hari ;

Marler, Vicky ;

Sosa, Julie Ann .

ONCOTARGETS AND THERAPY, 2011, 4 :209-215

[8] Unusual Adverse Event With Vandetanib in Metastatic Medullary Thyroid Cancer [J].

Duplomb, Sophie ;

Benoit, Amandine ;

Mechtouff-Cimarelli, Laura ;

Cho, Tae-Hee ;

Derbel, Olfa ;

Peix, Jean Louis ;

de la Fouchardiere, Christelle .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (02) :E21-E23

[9] ZD6474 - clinical experience to date [J].

Heymach, JV .

BRITISH JOURNAL OF CANCER, 2005, 92 (Suppl 1) :S14-S20

[10]

Lauri Scudder D., 2011, GAME CHANGERS ONCOLO

← 1 2 3 →